- PR Newswire•3 days ago
SUNNYVALE, Calif., Feb. 16, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today data from a prospective, Phase II, 17-center study which showed that treatment with the CyberKnife® System for low- and intermediate-risk prostate cancer provides excellent long-term results. At five years, the disease-free survival rate for low-risk prostate cancer patients was 100 percent and for intermediate-risk patients was 88.5 percent. A low prostate specific antigen (PSA) value is associated with a reduced risk of cancer recurrence or metastases. According to the study, the five-year median PSA was 0.1 ng/mL for low- and intermediate-risk prostate cancer patients receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife System.
- Motley Fool•7 days ago
Making surgical robots is an exciting business, but only one is investment-worthy right now.
- PR Newswire•7 days ago
SUNNYVALE, Calif., Feb. 13, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that Kevin Waters, Senior Vice President and Chief Financial Officer, is scheduled to meet with investors ...
ARAY : Summary for Accuray Incorporated - Yahoo Finance
Accuray Incorporated (ARAY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||3.85 x 100|
|Ask||5.95 x 200|
|Day's Range||5.45 - 5.55|
|52 Week Range||4.45 - 6.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-17.40|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|